A Review of the Clinical Utility of Tubule-Specific Biomarkers in Sickle Cell Nephropathy.

Authors

Belinda Owusuaa Antwi, Kwame Afriyie Kyei Baffour, Anthony Yaw Dziworshie, Sandy Baffour Adu, Godfred Amoah Appiah

Published in

BioMed research international. Volume 2026. Issue 1. Pages e3790001.

Abstract

Sickle cell nephropathy affects about 30%-50% of individuals living with sickle cell disease (SCD), raising the risk of mortality in this population. Traditional renal markers, such as serum creatinine and glomerular filtration rate, fail to detect renal damage until substantial injury occurs. However, growing evidence suggests tubular injury precedes glomerular damage, offering opportunities for earlier intervention through novel biomarkers that detect subclinical renal stress before albuminuria onset. In this narrative review, we evaluated kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, N-acetyl-β-D-glucosaminidase, transforming growth factor-β, liver-type fatty acid binding protein, and monocyte chemoattractant protein-1 as early indicators of renal damage in individuals with SCD. Additionally, we examine the effect of existing SCD therapy on these biomarkers, highlighting their clinical relevance in sickle cell nephropathy.

PMID:
42644509
Bibliographic data and abstract were imported from PubMed on 26 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.